Blog / Archives
Biopharmaceuticals Resist Market Correction: M&A du jour Ardea (RDEA)
Biotech Outperforming Tech Lately: M&A Hit of the Day Ardea Biosciences The market continues its choppy trend with the QQQ's off 0.9% to $65 with some Internet high fliers like AMZN and NFLX...
Rayno Life Science Portfolio: CBST, GILD,HGSI, REGN SQNM
Biotech Rally Ignited By Clinical News and M&A Theme The biotech sector roared back today with major ETF's IBB ($122) up 2.4% and XBI ($78.6) up 5.1 % driven primarily by Gilead (GILD $52.23) up...
Risk Off: Profit Taking, Spain and Jobs Data//BIO Update April 11
Nice Recovery in biotech today with our mid-cap index up almost 1%. Without doing a lot of detailed analysis it looks like stocks that have major institutional sponsors are rallying. Smaller caps...
Financial Review of Pure Play Clinical Diagnostic Companies
Who to Watch Among the Pure Play DX Companies? High fliers with cache' among traders and investors: CPHD,EXAS. Value plays for earnings turn-around: ALR, QGEN. Niche companies: NEOG, SQNM....
Emerging Biomarker Diagnostics: BGMD and VRML
Early Stage Diagnostic Players With Novel Biomarkers We posted an overview on Seeking Alpha of two emerging diagnostic companies focused in novel clinical biomarkers which are FDA cleared. Products...
Rayno Life Science Portfolio: Diagnostics and Tools
Here is an update of our Diagnostics and Tools portfolio. Diagnostics and Tools have underperformed the biopharmaceuticals sector over the past 6 months with the exception of the companies acquired....
Rayno Biopharma Portfolio Update: ALXN, BIIB, CBST,REGN, VPHM
We have updated our Rayno Biopharmaceuticals Portfolio with total returns from inception 3/9/09 to 3/30/12. Biggest winners are Alexion (ALXN) Biogen (BIIB) , Cubist (CBST), Regeneron (REGN) and...
Rayno Life Science Portfolio: Alexion (ALXN), Response Genetics (RGDX)
Two Companies With Major Biotech Themes: Orphan Drugs (ALXN) and Targeted Cancer Therapy (RGDX) IBB ($122) Weak Down 1% - 52 Week High of $124 One of our Top Performers in the biopharmaceutical...
No Market Reaction To Supreme Court Patent Rejection For Dx Tests
Diagnostics Stocks Are Relatively Calm After Patent News: But Patents Still Matter The Supreme Court Ruling threw out two process patents on diagnostic tests because they were based on the laws of...
New Trends Or Head Fake: Treasury Yields Up, Gold Down, Equities Rule
There Is A Fork In the Road-Do you Take It? The past two days have shown some very dramatic trends in the market. But we will not discuss the parabolics of AAPL $589 stock up 8% in five days which...